Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Travelan is a hyperimmune bovine colostrum (HBC) product developed by Immuron Ltd. for the prevention of traveler's diarrhea. The active ingredient, IMM-124E, is a polyclonal antibody preparation harvested from the colostrum of dairy cows that have been immunized with a vaccine containing multiple strains of enterotoxigenic Escherichia coli (ETEC). When taken orally, these antibodies provide passive immunity by binding to bacterial surface antigens and toxins within the gastrointestinal tract, thereby neutralizing the pathogens and preventing their attachment to the intestinal mucosa. Although primarily designed to target ETEC, the antibodies in Travelan have demonstrated cross-reactivity against other major enteric pathogens, including Shigella, Salmonella, and Campylobacter species. The product is commercially available as a dietary supplement in tablet form in the United States, Australia, and Canada.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Travelan.